首页|血塞通联合阿加曲班治疗急性脑梗死的临床效果观察

血塞通联合阿加曲班治疗急性脑梗死的临床效果观察

扫码查看
目的 探讨血塞通联合阿加曲班治疗急性脑梗死的临床效果观察。方法 选取2020年3月—2021年12月衡水市第六人民医院收治的急性脑梗死患者124例为研究对象,采用随机数字表法分为联合组(62例)、对照组(62例)。对照组给予常规治疗和阿加曲班,联合组在对照组的基础上加用血塞通进行治疗。比较两组患者治疗前及治疗14 d后美国国立卫生研究院卒中量表(NIHSS)评分、脑循环动力学各项指标、血清肿瘤坏死因子样弱凋亡诱导剂(sTWEAK)水平、总有效率及不良反应。结果 治疗14 d后,联合组总有效率90。32%(56/62)高于对照组总有效率70。97%(44/62),差异有统计学意义(χ2=7。440,P<0。05)。治疗前,两组NIHSS评分、最小血流速度(Vmin)、最小血流量(Qmin)、脑血管阻力(R)、sTWEAK水平比较,差异均无统计学意义(均P>0。05);治疗后,联合组NIHSS评分[(4。21±1。02)vs(6。98±1。21)分]、R[(1 802。50±188。64)vs(1 925。41±199。86)Pa·s/ml]、sTWEAK[(78。21±10。42)vs(125。98±13。25)]水平低于对照组,Vmin[(10。51±1。73)vs(9。25±1。64)cm/s]、Qmin[(4。75±0。98)vs(4。26±0。95)ml/s]水平高于对照组,且两组治疗前后差值比较,差异均有统计学意义(均P<0。05)。两组不良反应总发生率比较,差异无统计学意义(P>0。05)。结论 血塞通联合阿加曲班治疗急性脑梗死疗效较好,可改善患者脑部血流循环状态以及神经功能恢复。
Clinical efficacy of Xuesaitong combined with Argatroban in acute cerebral infarction
Objective To explore the clinical efficacy of Xuesaitong combined with Argatroban in acute cerebral infarction.Methods From March 2020 to December 2021,124 patients with acute cerebral infarction admitted to the Sixth People's Hospital of Hengshui were selected for subjects.Randomized numerical method was used to divide the patients into combined group(62 cases)and control group(62 cases).Control group was given conventional treatment and Argatroban,and combined group was treated with Xuesaitong in addition to control group.National Institute of Health Stroke Scale(NIHSS)scores,cerebral circulation dynamics indices,soluble tumor necrosis factor-like weak inducer of apoptosis(sTWEAK)levels,overall efficiency,and adverse effect were compared between the two groups of patients before treatment and after 14 days of treatment.Results After 14 days of treatment,the overall efficiency of 90.32%(56/62)in combined group was higher than the overall efficiency of 70.97%(44/62)in control group,and the difference was statistically significant(χ2=7.440,P<0.05).There was no statistically significant difference in NIHSS scores,minimum blood flow velocity(Vmin),minimum blood flow(Qmin),cerebrovascular resistance(R),and sTWEAK levels between the two groups before treatment(all P>0.05).After treatment,NIHSS scores[(4.21±1.02)vs.(6.98±1.21)],R[(1 802.50)±188.64)vs.(1 925.41±199.86)Pa·s/ml],and sTWEAK levels[(78.21±10.42)vs.(125.98±13.25)]in combined group were lower than those in control group,and the levels of Vmin[(10.51±1.73)vs.(9.25±1.64)cm/s],and levels of Qmin[(4.75±0.98)vs(4.26±0.95)ml/s]were higher than those of control group,and the difference between the two groups before and after treatment was also statistically significant(all P<0.05).The difference in the total incidence of adverse reactions between the two groups was not statistically significant(P>0.05).Conclusions The efficacy of Xuesaitong combined with Argatroban for acute cerebral infarction is good,which can improve the patients'cerebral blood circulation status as well as the recovery of neurological function.

Acute cerebral infarctionXuesaitongArgatrobansTWEAK levelCerebral circulation dynamics

李娇、山彩霞、曹飞、赵志敏

展开 >

053200 衡水市第六人民医院药剂科

053200 衡水市第六人民医院中药房

053200 衡水市第六人民医院神经内科

急性脑梗死 血塞通 阿加曲班 sTWEAK水平 脑循环动力学

2025

神经疾病与精神卫生
齐齐哈尔医学院

神经疾病与精神卫生

影响因子:0.579
ISSN:1009-6574
年,卷(期):2025.25(1)